Oculis appoints Rebecca Weil as CCO
Swiss ophthalmology firm Oculis Holding (Nasdaq: OCS) today announced the appointment of Rebecca Weil to the role of chief commercial officer.
In this key role, Ms Weil will lead the organization to commercial readiness from designing launch strategies for the USA and globally, and building the required commercial infrastructure to bring all of Oculis’ ground-breaking ophthalmic product candidates to markets worldwide.
Ms Weil is a seasoned commercial executive with 20 years of experience in biotech and large pharmaceutical companies at the global, regional, and local levels. Prior to joining Oculis, she was the senior vice president, head of global marketing, for Swiss biotech Idorsia (SIX: IDIA), where she built the team, defined the go-to-market strategies and launched the company’s first two products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze